TTNP : Summary for TITAN PHARMA INC - Yahoo Finance

U.S. Markets close in 23 mins.

Titan Pharmaceuticals, Inc. (TTNP)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.400.00 (0.00%)
As of 3:24PM EDT. Market open.
People also watch
VNDABDSIIMUCONCSAEZS
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.40
Open3.45
Bid3.40 x 100
Ask3.45 x 1600
Day's Range3.35 - 3.45
52 Week Range3.15 - 8.74
Volume28,124
Avg. Volume88,806
Market Cap72.08M
Beta1.59
PE Ratio (TTM)16.92
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube3 days ago

    ETFs with exposure to Titan Pharmaceuticals, Inc. : March 27, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Titan Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to TTNP-US. Comparing the performance and risk of Titan Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Zacks Small Cap Research3 days ago

    TTNP: 2016 Results; Deep Dive on Development Programs

    Titan Pharmaceuticals, Inc. (TTNP) reported full-year 2016 results on March 16, 2017 and later participated in an earnings call following the market close.  Total revenues, which consisted of a milestone payment and Probuphine royalties were $15.1 million compared to our estimates of $16.1 million.  The difference was due to fourth quarter royalty revenues of $35,000 vs. our estimates of $1.1 million.  R&D expenses of $6.1 million rose 31% over the prior year due to development expenses related to new ProNeura products. Free cash flow for 2016 was $6.1 million, generated by the $15 million in milestone payments by Braeburn in the second quarter paid upon FDA approval of Probuphine.  Cash levels increased over the year as a result of the positive cash flows from operations, from $7.9 million at the end of 2015 to $14.0 million at year end 2016.

  • Titan Pharmaceuticals, Inc. :TTNP-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017
    Capital Cube10 days ago

    Titan Pharmaceuticals, Inc. :TTNP-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis Titan Pharmaceuticals, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Titan Pharmaceuticals, Inc. – Vanda Pharmaceuticals Inc., Celldex Therapeutics, Inc., DURECT Corporation, Paratek Pharmaceuticals Inc, Novartis AG Sponsored ADR, Johnson & Johnson and Elite Pharmaceuticals, Inc. (VNDA-US, CLDX-US, ... Read more (Read more...)